Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.20EUR
−102.06 MEUR
25.05 M
About KINNATE BIOPHARMA INC
Sector
Headquarters
San Diego
Employees (FY)
27
Website
Founded
2018
FIGI
BBG00YD4G6V7
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 6KB is 2.44 EUR — it hasn't changed in the past 24 hours. Watch KINNATE BIOPHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange KINNATE BIOPHARMA INC stocks are traded under the ticker 6KB.
We've gathered analysts' opinions on KINNATE BIOPHARMA INC future price: according to them, 6KB price has a max estimate of 1.86 EUR and a min estimate of 1.86 EUR. Watch 6KB chart and read a more detailed KINNATE BIOPHARMA INC stock forecast: see what analysts think of KINNATE BIOPHARMA INC and suggest that you do with its stocks.
6KB stock is 0% volatile and has beta coefficient of 4.11. Track KINNATE BIOPHARMA INC stock price on the chart and check out the list of the most volatile stocks — is KINNATE BIOPHARMA INC there?
Yes, you can track KINNATE BIOPHARMA INC financials in yearly and quarterly reports right on TradingView.
KINNATE BIOPHARMA INC is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
6KB earnings for the last quarter are −0.35 EUR per share, whereas the estimation was −0.35 EUR resulting in a 0% surprise. The estimated earnings for the next quarter are −0.36 EUR per share. See more details about KINNATE BIOPHARMA INC earnings.
6KB net income for the last quarter is −15.45 M EUR, while the quarter before that showed −29.07 M EUR of net income which accounts for 46.84% change. Track more KINNATE BIOPHARMA INC financial stats to get the full picture.
No, 6KB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 7, 2024, the company has 27.00 employees. See our rating of the largest employees — is KINNATE BIOPHARMA INC on this list?
Like other stocks, 6KB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KINNATE BIOPHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KINNATE BIOPHARMA INC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KINNATE BIOPHARMA INC stock shows the sell signal. See more of KINNATE BIOPHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.